TOKYO, July 5, 2017 /PRNewswire/ -- Anaeropharma Science, Inc., a company dedicated to the development of novel therapeuticsto target hypoxic solid tumors, announced on July 5 it has secured US$13.2 million in new capital. The participants in the financing round include three new investors, Novartis, Shinsei Corporate
About Anaeropharma Science, Inc.
Anaeropharma is a biopharmaceutical company engaged in research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant "Bifidobacterium". This approach offers broad potential to be more effective to solid tumors and less toxic to healthy tissues than conventional anti-cancer drugs. APS001F, a recombinant "Bifidobacterium" to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is its leading development product which is under a clinical trial in the U.S., and additional programs in the immune oncology area such as immune checkpoint blockers and other immune-related molecules expressing recombinant "Bifidobacteria" are under active development.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/anaeropharma-science-announces-closing-of-financing-300483280.html
SOURCE Anaeropharma Science, Inc.
Subscribe to our Free Newsletters!
Corporate and Workplace Employee wellness programs are designed to improve health of employees, ...
Soft tissue sarcoma is a rare cancer of connective tissue that can affect soft tissues such as fat, ...
To get rid of facial fat on cheek and chin, practice face yoga, eat right and keep your body ...View All